VRG-50635 is under clinical development by Verge Analytics and currently in Phase I for Frontotemporal Dementia (FTD). According to GlobalData, Phase I drugs for Frontotemporal Dementia (FTD) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the VRG-50635 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VRG-50635 overview

VRG-50635 is under development for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia. It is a first generation candidate and administered by oral route. It acts by targeting 1 phosphatidylinositol 3 phosphate 5 kinase (PIKFYVE). It is being developed based on CONVERGE artificial intelligence (AI) platform.

Verge Analytics overview

Verge Analytics (Verge) is a drug discovery company that focuses on the discovery of treatments for neurodegenerative diseases using human genomic data and machine learning. The company combines large-scale molecular, genomic and genetic data on multiple platforms and technologies to map disease-causing genes. Its pipeline platforms include the conVerge platform. The company’s pipeline programs include ALS PIKfyve, Parkinson’s disease, Schizophrenia, Neurodegenerative diseases, Psoriasis, Ulcerative Colitis, Atopic Dermatitis and Crohn’s disease. The company operates in the US. Verge is headquartered in South San Francisco, California, the US.

For a complete picture of VRG-50635’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.